Please use this identifier to cite or link to this item:
https://scholars.lib.ntu.edu.tw/handle/123456789/594653
Title:
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial